_:n9a0481006b9a482a86033b3cd3f9387cxb0
<http://schema.org/mainEntityOfPage>
<https://www.fiercepharma.com/pharma/amgen-announces-new-data-from-phase-2-blincyto%E2%84%A2-blinatumomab-immunotherapy-study-patients>